CN114761412B - 取代的大环化合物和相关治疗方法 - Google Patents

取代的大环化合物和相关治疗方法 Download PDF

Info

Publication number
CN114761412B
CN114761412B CN202080081320.8A CN202080081320A CN114761412B CN 114761412 B CN114761412 B CN 114761412B CN 202080081320 A CN202080081320 A CN 202080081320A CN 114761412 B CN114761412 B CN 114761412B
Authority
CN
China
Prior art keywords
compound
formula
another embodiment
ring
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080081320.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114761412A (zh
Inventor
刘易斯·D·彭宁顿
崔永吉
黄霍安
布莱恩·M·阿奎拉
英戈·马格
胡元
詹姆斯·R·伍兹
罗曼·A·瓦利林
布莱恩·肯尼斯·雷默
乔治·马丁·本齐恩
迈克尔·R·霍尔
乔纳森·沃德·莱曼
达尔吉特·马塔鲁
斯里尼瓦斯·卡拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of CN114761412A publication Critical patent/CN114761412A/zh
Application granted granted Critical
Publication of CN114761412B publication Critical patent/CN114761412B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080081320.8A 2019-11-25 2020-11-25 取代的大环化合物和相关治疗方法 Active CN114761412B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939825P 2019-11-25 2019-11-25
US62/939,825 2019-11-25
US202063030979P 2020-05-28 2020-05-28
US63/030,979 2020-05-28
PCT/US2020/062320 WO2021108628A1 (en) 2019-11-25 2020-11-25 Substituted macrocyclic compounds and related methods of treatment

Publications (2)

Publication Number Publication Date
CN114761412A CN114761412A (zh) 2022-07-15
CN114761412B true CN114761412B (zh) 2024-10-11

Family

ID=73856348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080081320.8A Active CN114761412B (zh) 2019-11-25 2020-11-25 取代的大环化合物和相关治疗方法

Country Status (24)

Country Link
US (3) US11542276B2 (cg-RX-API-DMAC7.html)
EP (2) EP4628167A3 (cg-RX-API-DMAC7.html)
JP (2) JP7787812B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260083444A (cg-RX-API-DMAC7.html)
CN (1) CN114761412B (cg-RX-API-DMAC7.html)
AU (2) AU2020394444B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009938A2 (cg-RX-API-DMAC7.html)
DK (1) DK4065585T3 (cg-RX-API-DMAC7.html)
ES (1) ES3041424T3 (cg-RX-API-DMAC7.html)
FI (1) FI4065585T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251156T1 (cg-RX-API-DMAC7.html)
HU (1) HUE073461T2 (cg-RX-API-DMAC7.html)
IL (2) IL293240B2 (cg-RX-API-DMAC7.html)
LT (1) LT4065585T (cg-RX-API-DMAC7.html)
MA (1) MA57908B1 (cg-RX-API-DMAC7.html)
MD (1) MD4065585T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022006206A (cg-RX-API-DMAC7.html)
PT (1) PT4065585T (cg-RX-API-DMAC7.html)
RS (1) RS67202B1 (cg-RX-API-DMAC7.html)
SA (1) SA522432691B1 (cg-RX-API-DMAC7.html)
SI (1) SI4065585T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500340T1 (cg-RX-API-DMAC7.html)
WO (1) WO2021108628A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202206482B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116635393A (zh) * 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
EP4247801A4 (en) * 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
WO2022232025A1 (en) * 2021-04-26 2022-11-03 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
AU2022281345A1 (en) * 2021-05-26 2023-11-30 Alkermes, Inc. Substituted fused bicyclic macrocyclic compounds and related methods of treatment
JP7833486B2 (ja) * 2021-05-26 2026-03-19 アルカーメス,インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
WO2023167925A1 (en) * 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素2型受體促效劑之給藥
CN120584118A (zh) * 2022-11-23 2025-09-02 沃泰克斯药物股份有限公司 食欲素受体2的经取代的大环胺调节剂
JPWO2024128305A1 (cg-RX-API-DMAC7.html) 2022-12-16 2024-06-20
JP2026506356A (ja) 2023-01-31 2026-02-24 ジャズ ファーマシューティカルズ アイルランド リミテッド 大環状オレキシン受容体アゴニスト及びその使用
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) * 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン2受容体アゴニスト
TW202502342A (zh) 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素2受體促效劑用於改善睡眠期間之呼吸功能的用途
AU2024361979A1 (en) * 2023-10-20 2026-03-05 Alkermes, Inc. Compound for use in treating narcolepsy
WO2025096445A1 (en) 2023-10-30 2025-05-08 Alkermes, Inc. Synthesis of intermediates for the preparation of macrocyclic compounds
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
TW202547576A (zh) * 2024-04-04 2025-12-16 日商橘生藥品工業股份有限公司 取代磺醯胺巨環狀化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
US20260144795A1 (en) 2024-11-27 2026-05-28 H. Lundbeck A/S Spiromacrocyclic orexin 2 receptor agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107787322A (zh) * 2015-06-17 2018-03-09 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
CN108699065A (zh) * 2015-12-18 2018-10-23 诺华股份有限公司 作为激酶抑制剂的三环类化合物和组合物

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
WO1999023114A1 (en) 1997-10-31 1999-05-14 Biomira Inc. Muc-1 derivatives and their use in treating cancer-associated muc-1 mucin-induced immunosuppression
AU2903999A (en) 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
CA2324205A1 (en) 1998-04-03 1999-10-14 University Of Washington Circularly permuted biotin binding proteins
EP1151012A4 (en) 1998-11-19 2003-01-08 Smithkline Beecham Corp ANTAGONIST ANTIBODIES OF RHAMM
US6428985B1 (en) 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
JP2003530384A (ja) 2000-04-06 2003-10-14 メルク フロスト カナダ アンド カンパニー カテプシンシステインプロテアーゼ阻害薬
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
HUP0400698A3 (en) 2001-02-06 2006-01-30 Merck Patent Gmbh Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity
WO2003010201A2 (en) 2001-07-20 2003-02-06 Absorber, Ab Blood group antigen fusion polypeptides and methods of use thereof
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7638323B2 (en) 2002-08-09 2009-12-29 Recopharma Ab Fusion proteins and methods of producing same
WO2004044006A1 (en) 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2005034863A2 (en) 2003-10-03 2005-04-21 Jarikuma Corporation Countermeasures against malaria
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
US8454963B2 (en) 2003-11-13 2013-06-04 Musc Foundation For Research Development Tissue targeted complement modulators
US7576183B2 (en) 2003-12-24 2009-08-18 Los Alamos National Security, Llc Structure-based receptor MIMICS targeted against bacterial superantigen toxins
US7851463B2 (en) 2004-10-14 2010-12-14 Abbott Gmbh & Co. Kg Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
CA2588449A1 (en) 2004-11-24 2006-06-01 Therakine Corporation An implant for intraocular drug delivery
KR20080013853A (ko) 2005-02-23 2008-02-13 사이케노믹스, 인코퍼레이티드 복수매개물질 도파민 수송체 저해물질 및 이와 관련된 용도
US7829679B2 (en) 2005-08-12 2010-11-09 Riken Mucin-type glycoprotein and use thereof
JPWO2007063907A1 (ja) 2005-11-30 2009-05-07 塩野義製薬株式会社 ペプチド糖鎖付加体およびそれを有効成分とする医薬
ATE437889T1 (de) 2005-12-02 2009-08-15 Apceth Gmbh & Co Kg Chemokin-mucin fusionsproteine mit einer gpi- ankerdomäne und deren verwendung als tumor-immun- adjuvanzien oder in der geweberegeneration
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
WO2008133928A2 (en) 2007-04-27 2008-11-06 The Gi Company, Inc. Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
CA2695374A1 (en) 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
BRPI0914889A2 (pt) 2008-06-17 2015-11-24 Otsuka Chemical Co Ltd peptídeo glp-1 adicionado de cadeia oligossacarídica
RU2518471C2 (ru) * 2008-08-14 2014-06-10 Тиботек Фармасьютикалз Макроциклические индольные производные, применимые в качестве ингибиторов вируса гепатита с
JP2012525415A (ja) 2009-05-01 2012-10-22 オプソテツク・コーポレイシヨン 眼科疾患を処置または予防するための方法
AU2010264095B2 (en) 2009-06-26 2013-07-11 Biogen Ma Inc. Heterocyclic sulfonamides, uses and pharmaceutical compositions thereof
KR20120107122A (ko) 2009-12-22 2012-09-28 노파르티스 아게 치료법에서 사용하기 위한 4가 cd47―항체 불변 영역 융합 단백질
US20130089554A1 (en) 2009-12-29 2013-04-11 Emergent Product Development Seattle, Llc RON Binding Constructs and Methods of Use Thereof
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
KR101333958B1 (ko) 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Fc 융합단백질
EP2457579A1 (en) 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
TWI622597B (zh) 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
EP2836485B1 (en) 2012-03-17 2018-01-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
CN104640561A (zh) 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
JP2016526014A (ja) 2013-04-24 2016-09-01 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−10組成物及びその使用
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
EP3027647A4 (en) 2013-07-31 2017-01-04 Amgen Inc. Stabilization of fc-containing polypeptides
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
JP6715239B2 (ja) 2014-09-11 2020-07-01 ヤンセン ファーマシューティカ エヌ.ベー. 置換2−アザ二環式化合物及びオレキシン受容体調節因子としてのその使用
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2016101119A1 (en) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Fused heteroaryl derivatives as orexin receptor antagonists
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
CA2989146A1 (en) 2015-06-12 2016-12-15 Board Of Regents, The University Of Texas System Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
WO2017035354A1 (en) * 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US10428023B2 (en) 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
CN111132975B (zh) 2017-09-28 2023-05-23 勃林格殷格翰国际有限公司 N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
JP7170996B2 (ja) 2017-12-12 2022-11-15 国立大学法人 筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
WO2019191327A1 (en) 2018-03-27 2019-10-03 Board Of Regents, The University Of Texas System Ox2r compounds
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
EP4010314B1 (en) 2019-08-08 2024-02-28 Merck Sharp & Dohme LLC Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP2022547604A (ja) 2019-09-13 2022-11-14 武田薬品工業株式会社 過度の眠気の治療のためのオレキシン2受容体アゴニストの使用
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
US11352357B2 (en) 2019-11-27 2022-06-07 Sumitomo Dainippon Pharma Co., Ltd. Cycloalkylurea derivative
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
CA3167050A1 (en) 2020-01-10 2021-07-15 Takeda Pharmaceutical Company Limited A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome p450
CN119235864A (zh) 2020-07-17 2025-01-03 卫材R&D管理有限公司 取代的哌啶化合物及其用途
WO2022040058A1 (en) 2020-08-18 2022-02-24 Merck Sharp & Dohme Corp. Cyclopentapyrrole orexin receptor agonists
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116635393A (zh) 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
JP2022064180A (ja) 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
WO2022094012A1 (en) 2020-11-02 2022-05-05 Merck Sharp & Dohme Corp. Macrocyclic urea orexin receptor agonists
EP4247801A4 (en) * 2020-11-23 2024-10-30 Merck Sharp & Dohme LLC 3-AMINO PYRROLIDINE AND MACROCYCLIC PIPERIDINE OREXIN RECEPTOR AGONISTS
US12552767B2 (en) 2020-12-03 2026-02-17 Merck Sharp & Dohme Llc 3-heteroaryl pyrrolidine and piperidine orexin receptor agonists
US12692262B2 (en) 2020-12-16 2026-07-28 Merck Sharp & Dohme Llc Substituted ureas as orexin receptor agonists
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
JP7860139B2 (ja) 2021-03-03 2026-05-15 リサーチ トライアングル インスティテュート オレキシン受容体アゴニストとしてのアリールスルホンアミド
WO2022207935A1 (en) 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
MX2023012971A (es) 2021-05-03 2024-01-16 Jazz Pharmaceuticals Ireland Ltd Agonistas del receptor de orexina y sus usos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107787322A (zh) * 2015-06-17 2018-03-09 辉瑞大药厂 三环化合物以及它们作为磷酸二酯酶抑制剂的用途
CN108699065A (zh) * 2015-12-18 2018-10-23 诺华股份有限公司 作为激酶抑制剂的三环类化合物和组合物

Also Published As

Publication number Publication date
JP2023502441A (ja) 2023-01-24
BR112022009938A2 (pt) 2022-09-13
FI4065585T3 (fi) 2025-09-26
ZA202206482B (en) 2025-10-29
EP4065585B1 (en) 2025-08-20
AU2025203295A1 (en) 2025-05-29
AU2025203295B2 (en) 2026-07-16
EP4065585A1 (en) 2022-10-05
DK4065585T3 (da) 2025-09-08
LT4065585T (lt) 2025-10-10
US11542276B2 (en) 2023-01-03
PT4065585T (pt) 2025-09-30
ES3041424T3 (en) 2025-11-12
MA57908B1 (fr) 2025-09-30
US12054495B2 (en) 2024-08-06
JP2025186272A (ja) 2025-12-23
CN114761412A (zh) 2022-07-15
IL293240B2 (en) 2025-09-01
EP4628167A2 (en) 2025-10-08
US20210155636A1 (en) 2021-05-27
IL293240A (en) 2022-07-01
AU2020394444B2 (en) 2025-05-29
SA522432691B1 (ar) 2025-05-27
JP7787812B2 (ja) 2025-12-17
EP4628167A3 (en) 2025-12-03
HRP20251156T1 (hr) 2025-11-21
HUE073461T2 (hu) 2026-01-28
KR102969640B1 (ko) 2026-05-28
NZ787541A (en) 2025-10-31
SMT202500340T1 (it) 2025-11-10
MX2022006206A (es) 2022-09-09
AU2020394444A1 (en) 2022-05-19
KR20220106793A (ko) 2022-07-29
US20230339969A1 (en) 2023-10-26
KR20260083444A (ko) 2026-06-05
IL320038A (en) 2025-06-01
MD4065585T2 (ro) 2025-12-31
WO2021108628A1 (en) 2021-06-03
RS67202B1 (sr) 2025-10-31
SI4065585T1 (sl) 2025-11-28
US20250092063A1 (en) 2025-03-20
CA3155885A1 (en) 2021-06-03
IL293240B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CN114761412A (zh) 取代的大环化合物和相关治疗方法
TWI730937B (zh) Gpr6 的四氫吡啶並吡調節劑
JP2024501641A (ja) 置換大環状化合物及び関連する治療方法
CN112512589A (zh) 二聚体免疫调节化合物对抗基于cereblon的机制
TWI833819B (zh) 用於治療與apj受體活性相關的病狀的化合物及組成物
TW201605859A (zh) 作為酪蛋白激酶1δ/ε抑制劑之新穎經取代之吡唑并-哌
JP2021535118A (ja) KEAP1−Nrf2タンパク質−タンパク質相互作用の阻害剤
TW202000659A (zh) 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
CN115348961A (zh) 杂环pad4抑制剂
CN107001316A (zh) 作为抗菌剂的喹诺酮衍生物
US20230113609A1 (en) Sstr5 antagonists
JP2024520395A (ja) 置換される縮合二環式大環状化合物および関連のある治療方法
CN112638381A (zh) 毒蕈碱性乙酰胆碱m1受体拮抗剂
US8088920B2 (en) 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
KR20230134500A (ko) Irak4 억제제로서의 이미다조[1,2-a]피리딘 유도체및 질환의 치료에서의 그의 용도
CN115485273A (zh) 作为sstr4激动剂的n-(杂环基和杂环基烷基)-3-苯甲基吡啶-2-胺衍生物
HK40129946A (en) Substituted macrocyclic compounds and related methods of treatment
HK40104123A (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
EA047646B1 (ru) Замещенные макроциклические соединения и связанные с ними способы лечения
HK40079289B (en) Substituted macrocyclic compounds and related methods of treatment
HK40079289A (en) Substituted macrocyclic compounds and related methods of treatment
WO2025124571A1 (zh) Nmda受体拮抗剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 900 Winter Street, Waltham, Massachusetts, United States

Applicant after: Alkermes, Inc.

Address before: 852 winter street, Waltham, Massachusetts, USA

Applicant before: Alkermes, Inc.

GR01 Patent grant
GR01 Patent grant